Loading
The main open trial for NUT carcinoma, pairing a BET inhibitor that attacks the BRD4-NUT fusion directly with the platinum chemotherapy patients would otherwise receive alone.
NUT carcinoma is driven by a fusion of NUTM1 to BRD4 or another BET protein, so BET bromodomain inhibitors are its most rational drugs; single agents produced responses but not durable ones. This National Cancer Institute study tests ZEN003694 with platinum-based chemotherapy in advanced NUT carcinoma, with a dose-finding phase 1 leading into phase 2. It is recruiting.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares ZEN-3694, NUT carcinoma (midline carcinoma with NUTM1 rearrangement), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), National Cancer Institute (NIH) and the tag owner-request.
Shares NUT carcinoma (midline carcinoma with NUTM1 rearrangement) and the tag owner-request.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag owner-request.
Shares National Cancer Institute (NIH) and the tag owner-request.
Shares Cytotoxic chemotherapy and the tag owner-request.
Shares Cytotoxic chemotherapy and the tag owner-request.
Shares Cytotoxic chemotherapy and the tag owner-request.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/